S&P 500   4,967.23
DOW   37,986.40
QQQ   414.65
North Carolina medical marijuana sales begin at Cherokee store
Biden sees a $35 price cap for insulin as a pivotal campaign issue. It’s not that clear-cut
Ukrainian and Western leaders laud US aid package while the Kremlin warns of 'further ruin'
'Civil War’ continues box-office campaign at No. 1
Conservative Brazilians laud Elon Musk at rally in support of ex-president Bolsonaro
Tens of thousands of Colombians protest against the leftist president's reform agenda
Stock market today: Asian shares shrug off Wall St blues as China leaves lending rate unchanged
S&P 500   4,967.23
DOW   37,986.40
QQQ   414.65
North Carolina medical marijuana sales begin at Cherokee store
Biden sees a $35 price cap for insulin as a pivotal campaign issue. It’s not that clear-cut
Ukrainian and Western leaders laud US aid package while the Kremlin warns of 'further ruin'
'Civil War’ continues box-office campaign at No. 1
Conservative Brazilians laud Elon Musk at rally in support of ex-president Bolsonaro
Tens of thousands of Colombians protest against the leftist president's reform agenda
Stock market today: Asian shares shrug off Wall St blues as China leaves lending rate unchanged
S&P 500   4,967.23
DOW   37,986.40
QQQ   414.65
North Carolina medical marijuana sales begin at Cherokee store
Biden sees a $35 price cap for insulin as a pivotal campaign issue. It’s not that clear-cut
Ukrainian and Western leaders laud US aid package while the Kremlin warns of 'further ruin'
'Civil War’ continues box-office campaign at No. 1
Conservative Brazilians laud Elon Musk at rally in support of ex-president Bolsonaro
Tens of thousands of Colombians protest against the leftist president's reform agenda
Stock market today: Asian shares shrug off Wall St blues as China leaves lending rate unchanged
S&P 500   4,967.23
DOW   37,986.40
QQQ   414.65
North Carolina medical marijuana sales begin at Cherokee store
Biden sees a $35 price cap for insulin as a pivotal campaign issue. It’s not that clear-cut
Ukrainian and Western leaders laud US aid package while the Kremlin warns of 'further ruin'
'Civil War’ continues box-office campaign at No. 1
Conservative Brazilians laud Elon Musk at rally in support of ex-president Bolsonaro
Tens of thousands of Colombians protest against the leftist president's reform agenda
Stock market today: Asian shares shrug off Wall St blues as China leaves lending rate unchanged
NASDAQ:AQST

Aquestive Therapeutics (AQST) Stock Price, News & Analysis

$4.11
-0.39 (-8.67%)
(As of 04/19/2024 08:50 PM ET)
Today's Range
$4.05
$4.54
50-Day Range
$2.51
$6.09
52-Week Range
$1.15
$6.23
Volume
2.34 million shs
Average Volume
2.20 million shs
Market Capitalization
$301.26 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$8.00

Aquestive Therapeutics MarketRank™ Stock Analysis

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
94.6% Upside
$8.00 Price Target
Short Interest
Healthy
3.10% of Shares Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
N/A
Insider Trading
Selling Shares
$429,750 Sold Last Quarter
Proj. Earnings Growth
Growing
From ($0.36) to ($0.32) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

2.48 out of 5 stars

Medical Sector

453rd out of 907 stocks

Pharmaceutical Preparations Industry

201st out of 419 stocks

AQST stock logo

About Aquestive Therapeutics Stock (NASDAQ:AQST)

Aquestive Therapeutics, Inc. operates as a pharmaceutical company in the United States and internationally. The company markets Sympazan, an oral soluble film formulation of clobazam for the treatment of lennox-gastaut syndrome; Suboxone, a sublingual film formulation of buprenorphine and naloxone for the treatment of opioid dependence; Zuplenz, an oral soluble film formulation of ondansetron for the treatment of nausea and vomiting associated with chemotherapy and post-operative recovery; and Azstarys, a once-daily product for the treatment of attention deficit hyperactivity disorder. Its proprietary product candidates comprise Libervant, a buccal soluble film formulation of diazepam for the treatment of seizures; KYNMOBI, a sublingual film formulation of apomorphine for the treatment of episodic off-periods in Parkinson's disease; and Exservan, an oral soluble film formulation of riluzole for the treatment of amyotrophic lateral sclerosis. The company's proprietary pipeline of complex molecule product includes AQST-108, a sublingual film formulation delivering systemic epinephrine for the treatment of conditions other than anaphylaxis; and Anaphylm, an epinephrine sublingual film for the emergency treatment of allergic reactions, including anaphylaxis. In addition, it develops Adrenaverse, an epinephrine prodrug platform. The company was incorporated in 2004 and is headquartered in Warren, New Jersey.

AQST Stock Price History

AQST Stock News Headlines

Now Open: Crypto emergency update
During the event on Tuesday, April 23 at 10 am ET, I’ll be giving away the name and ticker symbol of crypto that could surge in price. I believe it will be the best performing crypto of 2024.
Now Open: Crypto emergency update
During the event on Tuesday, April 23 at 10 am ET, I’ll be giving away the name and ticker symbol of crypto that could surge in price. I believe it will be the best performing crypto of 2024.
Q4 2023 Aquestive Therapeutics Inc Earnings Call
See More Headlines
Receive AQST Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Aquestive Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
3/05/2024
Today
4/21/2024
Next Earnings (Estimated)
5/07/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:AQST
Fax
N/A
Employees
135
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$8.00
High Stock Price Target
$10.00
Low Stock Price Target
$4.00
Potential Upside/Downside
+94.9%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
5 Analysts

Profitability

Net Income
$-7,870,000.00
Pretax Margin
-15.07%

Debt

Sales & Book Value

Annual Sales
$50.58 million
Book Value
($1.59) per share

Miscellaneous

Free Float
67,151,000
Market Cap
$300.90 million
Optionable
Optionable
Beta
2.87
12 Stocks Corporate Insiders are Abandoning Cover

If a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know?

Get This Free Report

Key Executives

  • Mr. Daniel Barber (Age 48)
    CEO, President & Director
    Comp: $925.35k
  • Mr. Alexander Mark Schobel (Age 65)
    Chief Innovation & Technology Officer
    Comp: $672.69k
  • Ms. Lori J. Braender BSBA (Age 68)
    Esq., J.D., Senior VP, General Counsel, Chief Compliance Officer & Corporate Secretary
    Comp: $678.76k
  • Mr. A. Ernest Toth Jr. (Age 65)
    Chief Financial Officer
    Comp: $679.9k
  • Ms. Cassie Jung (Age 45)
    Senior Vice President of Operations
  • Mr. Peter E. Boyd (Age 58)
    Senior Vice President of IT, HR & Communications
  • Dr. Gary H. Slatko M.D. (Age 66)
    MBA, Chief Medical Officer
  • Dr. Stephen Wargacki (Age 46)
    Senior VP of Research & Development
  • Dr. Carl N. Kraus M.D. (Age 54)
    Chief Medical Officer
  • Mr. Robert Charles Arnold
    VP of Finance, Controller & Assistant Secretary

AQST Stock Analysis - Frequently Asked Questions

Should I buy or sell Aquestive Therapeutics stock right now?

5 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Aquestive Therapeutics in the last year. There are currently 5 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" AQST shares.
View AQST analyst ratings
or view top-rated stocks.

What is Aquestive Therapeutics' stock price target for 2024?

5 Wall Street research analysts have issued twelve-month target prices for Aquestive Therapeutics' shares. Their AQST share price targets range from $4.00 to $10.00. On average, they expect the company's share price to reach $8.00 in the next twelve months. This suggests a possible upside of 94.6% from the stock's current price.
View analysts price targets for AQST
or view top-rated stocks among Wall Street analysts.

How have AQST shares performed in 2024?

Aquestive Therapeutics' stock was trading at $2.02 at the beginning of 2024. Since then, AQST stock has increased by 103.5% and is now trading at $4.11.
View the best growth stocks for 2024 here
.

When is Aquestive Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, May 7th 2024.
View our AQST earnings forecast
.

How were Aquestive Therapeutics' earnings last quarter?

Aquestive Therapeutics, Inc. (NASDAQ:AQST) issued its earnings results on Tuesday, March, 5th. The company reported ($0.12) earnings per share for the quarter, missing analysts' consensus estimates of ($0.08) by $0.04. The business had revenue of $13.21 million for the quarter, compared to analysts' expectations of $11.79 million.

What guidance has Aquestive Therapeutics issued on next quarter's earnings?

Aquestive Therapeutics issued an update on its FY 2024 earnings guidance on Wednesday, March, 6th. The company provided EPS guidance of for the period. The company issued revenue guidance of $48.0 million-$51.0 million, compared to the consensus revenue estimate of $48.1 million.

What other stocks do shareholders of Aquestive Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Aquestive Therapeutics investors own include Sorrento Therapeutics (SRNE), Matinas BioPharma (MTNB), Zosano Pharma (ZSAN), Dynavax Technologies (DVAX), ADMA Biologics (ADMA), Bionano Genomics (BNGO), Organigram (OGI), Novan (NOVN), Outlook Therapeutics (OTLK) and KushCo (KSHB).

When did Aquestive Therapeutics IPO?

Aquestive Therapeutics (AQST) raised $60 million in an initial public offering on Wednesday, July 25th 2018. The company issued 4,000,000 shares at $14.00-$16.00 per share. BMO Capital Markets and RBC Capital Markets acted as the underwriters for the IPO and Wedbush PacGrow and JMP Securities were co-managers.

How do I buy shares of Aquestive Therapeutics?

Shares of AQST stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:AQST) was last updated on 4/22/2024 by MarketBeat.com Staff

From Our Partners